<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5C491D47-4D7E-4091-9314-A32C544EE11B"><gtr:id>5C491D47-4D7E-4091-9314-A32C544EE11B</gtr:id><gtr:name>UCSF Medical Center</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5C491D47-4D7E-4091-9314-A32C544EE11B"><gtr:id>5C491D47-4D7E-4091-9314-A32C544EE11B</gtr:id><gtr:name>UCSF Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7E1F3440-1745-4108-97E8-3F6C37A5B884"><gtr:id>7E1F3440-1745-4108-97E8-3F6C37A5B884</gtr:id><gtr:firstName>Wendy</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Noble</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700355"><gtr:id>B125E4C8-1783-477D-8088-4E35681A07B5</gtr:id><gtr:title>Investigating aberrant neuronal calcium regulation by calpain in Alzheimer s Disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700355</gtr:grantReference><gtr:abstractText>People who suffer from Alzheimer?s disease (AD) have severe memory loss and dementia. These symptoms are caused by the progressive and relentless death of nerve cells in the brain that we use for memory, recognition and most brain functions that give us our personality. 

My research is aimed at investigating why nerve cells die in AD because if we can prevent this cell death then we will have effective treatments for this devastating condition. 

I will focus on events that increase the amount of calcium inside nerve cells. Normally there is a balance between the amount of calcium entering and leaving nerve cells, but in AD this process is disrupted and excess calcium inside nerve cells causes them to die. 

My project will investigate the reasons for this calcium imbalance. I will also use animal models to test the effectiveness of drugs that should restore the calcium balance to determine whether they can prevent the nerve cell death that is characteristic of AD. This work may lead to a new strategy for treating AD which can be developed by the pharmaceutical industry and could result in a new generation of treatments for this devastating illness.</gtr:abstractText><gtr:technicalSummary>Alzheimer s disease (AD) affects approximately 750,000 people in the UK and the prevalence is rising each year. With a relatively late onset of symptomatic impairment in AD there is an opportunity for pharmacological intervention, however there is still a need for further investigation into pathogenic mechanisms in AD in order to identify therapeutic targets.
Elevated beta-amyloid (Abeta) levels are thought to initiate a pathogenic cascade in AD. Abeta stimulates calpain activation and there are sustained increases in calpain activation early in AD (Nixon et al., 2003). A tonic level of calpain activation is physiologically important in a number of processes, so it is essential to determine what causes sustained increases in calcium leading to the disease-associated calpain over-activation in AD. Calpain was recently shown to cleave and thus inactivate the sodium/calcium exchanger 3 (NCX3), preventing calcium extrusion from neurons and causing neurotoxicity (Bano et al., 2003). My preliminary data shows that calpain-mediated NCX3 cleavage is induced by Abeta in vitro and that NCX3 cleavage is significantly upregulated in AD brain. The research proposed in this experiment is designed to test the hypothesis that Abeta-induced calpain cleavage of the sodium/calcium exchanger (NCX3) is an early toxic event in the pathogenesis of AD, which consequentially results in neuronal death. To do this I will first establish the mechanism by which Abeta induces the accumulation of toxic concentrations of intraneuronal calcium via calpain-mediated cleavage of the NCX3 pump. I will then examine whether reduced expression of NCX3 sensitises neurons to Abeta-induced neurotoxicity using RNAi to suppress NCX3 expression. Constructs which suppress NCX3 to different degrees will be used to allow correlations between levels of NCX3 expression, intraneuronal calcium concentrations and neuronal death. I will establish whether increased NCX3 cleavage is a specific feature of AD or is common to other neurodegenerative disorders by measuring levels of cleaved protein in diseased brain. If NCX3 cleavage is increased specifically in AD brain I can then investigate whether it may be a good peripheral biomarker by examining cleaved NCX3 protein amounts in lymphocytes. Finally, to determine if calpain is a potential pharmacological target for AD I will treat transgenic mouse models of AD with calpain inhibitors using a novel technique. This research will help to unravel complex and poorly understood mechanisms and may lead to the discovery of a key step in the neurodegenerative pathway, with the potential for therapeutic development.</gtr:technicalSummary><gtr:fund><gtr:end>2010-10-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-10-29</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>346522</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCSF Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Physiology</gtr:department><gtr:description>NCX3 antibodies</gtr:description><gtr:id>80422873-A52F-4E8C-A513-784A64A72B96</gtr:id><gtr:impact>Atherton et al. (2014) Aging Cell.
Kurbatskaya et al. In preparation.</gtr:impact><gtr:outcomeId>cPx5ASdaEan-1</gtr:outcomeId><gtr:partnerContribution>The partner provided specific NCX antibodies</gtr:partnerContribution><gtr:piContribution>We screened postmortem neurodegenerative disease brain using specific NCX antibodies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Alzheimer's Research Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8E6F8E03-9473-4EE7-A40E-6A2FC9C6460C</gtr:id><gtr:impact>80 members of the public, including carers and families of people with dementia engaged in workshops, talks and Q+A sessions discussing current research in the field.

Web videos have been produced e.g. http://www.kcl.ac.uk/iop/news/records/2011/apr2011/AlzheimersOpenDay2011.aspx</gtr:impact><gtr:outcomeId>ms7wGQbyWWP</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2011,2012,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alzheimer's Society Research Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>742DA24E-67E8-4008-9279-663B2424BB15</gtr:id><gtr:impact>Over 100 members of the public engaged in discussions on our recent research findings.

N/A</gtr:impact><gtr:outcomeId>Kro2aw5mHY2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>73310</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship</gtr:description><gtr:end>2010-06-02</gtr:end><gtr:fundingOrg>Alzheimer?s Society</gtr:fundingOrg><gtr:id>54C35B75-7633-4A81-A6D8-A4E130AAEA40</gtr:id><gtr:outcomeId>E5afLsZdGRc</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>0391191E-90BA-43AF-8042-82F7FDF7EA1C</gtr:id><gtr:outcomeId>dphneF3xzQJ</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>148185</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>BFCCB5E7-E45E-4407-872B-931E35DF3530</gtr:id><gtr:outcomeId>NzvgLjBP5gx</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pilot grant</gtr:description><gtr:end>2010-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>93AE0E3F-6F2D-467F-99A1-45CDCAB29E5E</gtr:id><gtr:outcomeId>ThvokFKJiYG</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5332</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARUK Network Emergency Support Grant</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:fundingRef>ART-ESG2009-5</gtr:fundingRef><gtr:id>361DD2FA-525A-4320-ABB9-A0AD378955C5</gtr:id><gtr:outcomeId>CjZfrZY7Q8s</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60560</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Centre Studentship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A855E042-559F-4853-AD3A-3B8BC7D8F27F</gtr:id><gtr:outcomeId>EXeJYXSjDBG</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Participation in Ministerial Summit on Dementia Research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BDDAD3F9-0AB5-4912-865E-A81B52FD513F</gtr:id><gtr:outcomeId>544f7b8da7f6f1.68995742</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type><gtr:url>http://www.ilc-alliance.org/images/uploads/publication-pdfs/pdf_pdf_102.pdf</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Analysis of calcium associated protein amounts in control, Alzheimer's and other neurodegenerative disease brain</gtr:description><gtr:id>D9CF2760-EC40-424A-8993-8E2179C55172</gtr:id><gtr:impact>Ongoing.</gtr:impact><gtr:outcomeId>544f7bf0a37889.99622162</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Dataset- calcium regulated proteins in Alzheimer's brain</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>100CD89C-9DF6-4353-9255-22E89A97E714</gtr:id><gtr:title>Anti-inflammatory impact of minocycline in a mouse model of tauopathy.</gtr:title><gtr:parentPublicationTitle>Frontiers in psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c58c64d02a3edc3d0ae27f66455b7e2"><gtr:id>6c58c64d02a3edc3d0ae27f66455b7e2</gtr:id><gtr:otherNames>Garwood CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1664-0640</gtr:issn><gtr:outcomeId>pm_12462_22_21423446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6597615A-7F29-421E-B715-A0CAFD4BA898</gtr:id><gtr:title>Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e75e3b3ba79991d679d14b7a06170f9b"><gtr:id>e75e3b3ba79991d679d14b7a06170f9b</gtr:id><gtr:otherNames>Kurbatskaya K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2051-5960</gtr:issn><gtr:outcomeId>5805f0011fc136.06799467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F81DAC5-AB1B-4E76-ACCE-BDE116D632AA</gtr:id><gtr:title>The microtubule-associated protein tau is also phosphorylated on tyrosine.</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/052148e8fe0c44cfc5b23cde4a239956"><gtr:id>052148e8fe0c44cfc5b23cde4a239956</gtr:id><gtr:otherNames>Lebouvier T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn><gtr:outcomeId>pm_12462_12_19542604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22872E43-14B6-41FE-A6A3-8426CFBC69FC</gtr:id><gtr:title>Kinase activities increase during the development of tauopathy in htau mice.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33488ddeacacc670155f4970e13fadf6"><gtr:id>33488ddeacacc670155f4970e13fadf6</gtr:id><gtr:otherNames>Kelleher I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>pm_12462_12_17908241</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55AF3821-3E7B-4CA6-8DD1-2757EB09355F</gtr:id><gtr:title>Tau phosphorylation affects its axonal transport and degradation.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34ccfb591443e7db7227530de21d9b2a"><gtr:id>34ccfb591443e7db7227530de21d9b2a</gtr:id><gtr:otherNames>Rodr?guez-Mart?n T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_12462_22_23601672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC5FEFAB-0AD0-445B-AB74-482A7FB47D20</gtr:id><gtr:title>Calpain cleavage and inactivation of the sodium calcium exchanger-3 occur downstream of A? in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Aging cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72e099d8adf24b18c2633f7738324de4"><gtr:id>72e099d8adf24b18c2633f7738324de4</gtr:id><gtr:otherNames>Atherton J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-9718</gtr:issn><gtr:outcomeId>pm_12462_22_23919677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74F9BF3B-1C78-4B94-9578-6C92575B3A83</gtr:id><gtr:title>Transgenic mouse models of tauopathy in drug discovery.</gtr:title><gtr:parentPublicationTitle>CNS &amp; neurological disorders drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6181eaa28be814c0816a3195a16c5e23"><gtr:id>6181eaa28be814c0816a3195a16c5e23</gtr:id><gtr:otherNames>Noble W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1871-5273</gtr:issn><gtr:outcomeId>pm_12462_22_20522014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37317679-B01A-48FB-8986-4CFC435E9041</gtr:id><gtr:title>Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6181eaa28be814c0816a3195a16c5e23"><gtr:id>6181eaa28be814c0816a3195a16c5e23</gtr:id><gtr:otherNames>Noble W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>pm_12462_12_19001528</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2E8CC40-F8A8-4C20-A846-FCF38A213989</gtr:id><gtr:title>RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies.</gtr:title><gtr:parentPublicationTitle>Cellular and molecular life sciences : CMLS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fec3eaa854d91b6a6d2c6bb18a01c88c"><gtr:id>fec3eaa854d91b6a6d2c6bb18a01c88c</gtr:id><gtr:otherNames>Gallo JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1420-682X</gtr:issn><gtr:outcomeId>pm_12462_12_17453144</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9769763-E6BB-40AF-A673-6FAC7CABB2C2</gtr:id><gtr:title>Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddbe73f9b55b08283bcd0100833fc277"><gtr:id>ddbe73f9b55b08283bcd0100833fc277</gtr:id><gtr:otherNames>Cole AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>pm_12462_12_17683481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27CF297F-F202-44CC-9FDD-81DCE5F6E459</gtr:id><gtr:title>Linking amyloid and tau pathology in Alzheimer's disease: the role of membrane cholesterol in Abeta-mediated tau toxicity.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68ca09ebb1473b9780612d7b5d9dafef"><gtr:id>68ca09ebb1473b9780612d7b5d9dafef</gtr:id><gtr:otherNames>Wray S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>pm_12462_12_19657019</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700355</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>